Yamagami, Wataru

写真a

Affiliation

School of Medicine, Department of Obstetrics and Gynecology (Gynecology) (Shinanomachi)

Position

Assistant Professor/Senior Assistant Professor

External Links

Career 【 Display / hide

  • 2000.04
    -
    2002.05

    慶應義塾大学医学部産婦人科 研修医

  • 2002.06
    -
    2003.05

    大田原赤十字病院産婦人科 医員

  • 2003.06
    -
    2004.04

    埼玉社会保険病院産婦人科 医員

  • 2004.05
    -
    2005.03

    慶應義塾大学医学部産婦人科 助手

  • 2009.04
    -
    2011.03

    独立行政法人国立病院機構東京医療センター産婦人科 医員

display all >>

Academic Background 【 Display / hide

  • 1994.04
    -
    2000.03

    Keio University, Faculty of Medicine

    University, Graduated

  • 2005.04
    -
    2009.03

    Keio University, Graduate School, Division of Medicine

    Graduate School, Withdrawal after completion of doctoral course requirements, Doctoral course

Academic Degrees 【 Display / hide

  • 博士(医学), Keio University, Coursework, 2012.01

Licenses and Qualifications 【 Display / hide

  • 医師免許, 2000.04

  • 日本産科婦人科学会 産婦人科専門医, 2005.10

  • 日本臨床細胞学会 細胞診専門医, 2009.01

  • 日本がん治療認定医機構がん治療認定医, 2009.05

  • 日本婦人科腫瘍学会 婦人科腫瘍専門医, 2013.05

display all >>

 

Research Areas 【 Display / hide

  • Obstetrics and gynecology (Gynecologic Oncology)

  • Obstetrics and gynecology (Obstetrics and Gynecology)

Research Keywords 【 Display / hide

  • Cancer registry

  • Ovarian cancer

  • Fertility preserving treatment

  • Gynecologic oncology

  • Endometrial cancer

Research Themes 【 Display / hide

  • がん登録の普及と登録データの活用, 

    2013.04
    -
    Present

  • Fertility preserving treatment for endometrial cancer, 

    2011.04
    -
    Present

  • Minimal invasive surgery for gynecologic cancer, 

    2011.04
    -
    Present

  • Sentinel lymph node biopsy for gynecologic cancer, 

    2011.04
    -
    Present

 

Books 【 Display / hide

  • 産婦人科医のための社会保険ABC

    日本産科婦人科学会編, MEDICAL VIEW, 2021.01

    Scope: 婦人科悪性腫瘍(子宮頸癌・子宮体癌・卵巣癌),  Contact page: 174-195

  • Lynch Syndrome

    Yamagami W, Aoki D, Springer, 2020.08

    Scope: Lynch Syndrome-Associated Gynecological Malignancies,  Contact page: 71-78

  • 産科婦人科臨床5 悪性腫瘍

    藤井 和行,八重樫 伸生編, 中山書店, 2020.07

    Scope: 第3章子宮体癌 薬物療法,  Contact page: 148-158

  • 子宮鏡 新常識を極める 日本子宮鏡研究会編

    山上 亘, メジカルビュー社, 2019.09

    Scope: 悪性疾患の診断と子宮鏡,  Contact page: 68-71

  • 標準的医療説明の手順書 (一社】内科系学会社会保険連合編 2019年版

    山上 亘, 杏林舍, 2019.08

    Scope: 卵巣がん・子宮がんに対するがん化学療法(パクリタキセル・カルボプラチン),  Contact page: 168-171

display all >>

Papers 【 Display / hide

  • Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology: Annual patient report for 2017 and annual treatment report for 2012

    Nagase S., Ohta T., Takahashi F., Yaegashi N., Enomoto T., Katabuchi H., Kawana K., Kobayashi H., Kobayashi Y., Shozu M., Baba T., Morishige K., Yoshida Y., Yoshino K., Yamagami W., Tokunaga H.

    Journal of Obstetrics and Gynaecology Research (Journal of Obstetrics and Gynaecology Research)  47 ( 5 ) 1631 - 1642 2021.05

    ISSN  13418076

     View Summary

    Aim: To provide information including the trend of gynecological malignancies in Japan, we hereby present the Annual Patient Report for 2017 and the Annual Treatment Report for 2012, on the outcomes of patients who started treatment in 2012. Methods: The Japan Society of Obstetrics and Gynecology maintains an annual tumor registry, where information on gynecological malignancies from various participating institutions is gathered. The data of patients whose treatment with gynecologic malignancies was initiated in 2017 were analyzed retrospectively. Survival of the patients who started treatment with cervical, endometrial and ovarian cancer in 2012 was analyzed by using the Kaplan-Meier, log-rank and Wilcoxon tests. Results: Treatment was initiated in 2017 for 7710 patients with cervical cancer; 11 120 with endometrial cancer; 7029 with ovarian, tubal and peritoneal cancer; 2164 with ovarian borderline tumors; and with the others (213 vulvar cancer, 139 vaginal cancer, 366 uterine sarcoma, 41 uterine adenosarcoma and 131 trophoblastic diseases). This clinicopathological information was summarized as the patient annual report. The 5-year survival rates of the patients with cervical cancer were 92.9, 75.5, 58.2 and 26.7% for stages I, II, III and IV, respectively. The 5-year survival rates for the patients with endometrial cancer were 93.6, 85.6, 72.6 and 27.3% for stages I, II, III and IV, respectively. The 5-year survival rates for the patients with ovarian cancer (surface epithelial-stromal tumors) were 92.5, 83.5, 49.5 and 30.8% for stages I, II, III and IV, respectively. Conclusion: The annual tumor report is an important survey that provides knowledge on gynecological malignancy trends in Japan.

  • Atypical vessels in hysteroscopy: Usefulness in prediction of malignant diseases in patients treated with tamoxifen.

    Oka E, Sakai K, Yamagami W, Hirano T, Makabe T, Yoshihama T, Chiyoda T, Kataoka F, Banno K, Aoki D

    The journal of obstetrics and gynaecology research 47 ( 4 ) 1510 - 1515 2021.04

    ISSN  1341-8076

  • A prospective cohort study on the safety and efficacy of bevacizumab combined with chemotherapy in Japanese patients with relapsed ovarian, fallopian tube or primary peritoneal cancer

    Nanki Y., Nomura H., Iwasa N., Saotome K., Dozen A., Yoshihama T., Hirano T., Hashimoto S., Chiyoda T., Yamagami W., Kataoka F., Aoki D.

    Japanese journal of clinical oncology (Japanese journal of clinical oncology)  51 ( 1 ) 54 - 59 2021.01

    Research paper (scientific journal), Joint Work, Accepted,  ISSN  0368-2811

     View Summary

    © The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. OBJECTIVE: this prospective cohort study aimed to assess the safety and efficacy of bevacizumab combined with chemotherapy in Japanese patients with relapsed ovarian, fallopian tube or primary peritoneal cancer. METHODS: in this study, 40 Japanese patients with relapsed ovarian, fallopian tube or primary peritoneal cancer selected to receive bevacizumab with chemotherapy were enrolled. Patients in poor general condition were excluded. Each patient was monitored prospectively for adverse events, administration status, disease status and survival. Treatment was continued until intolerable adverse events or disease progression. The primary endpoint was safety. RESULTS: bevacizumab plus platinum-based chemotherapy was performed for 30 patients (median cycle; 16.5), while bevacizumab plus non-platinum chemotherapy was performed for 10 patients (median cycle; 5.5). Among bevacizumab-related adverse events, hypertension occurred in 80% of patients, proteinuria in 83%, mucositis in 25%, bleeding in 20%, thromboembolic events in 5.0% and fistula in 2.5%. Gastrointestinal perforation or other life-threatening lethal adverse events were not observed. Response rate and median progression-free survival were 73% and 19.3 months for patients with bevacizumab plus platinum-based chemotherapy, and 30% and 3.9 months for patients with bevacizumab plus non-platinum chemotherapy, respectively. There was no correlation between response rate and occurrence of adverse events such as hypertension or proteinuria. CONCLUSION: bevacizumab combined with chemotherapy was tolerable and effective for Japanese patients with relapsed ovarian cancer, fallopian tube cancer or primary peritoneal cancer. Hypertension and proteinuria are frequently occurred and managed properly for continuing treatment.

  • Germline multigene panel testing revealed a <i>BRCA2</i> pathogenic variant in a patient with suspected Lynch syndrome.

    Yoshihama T, Hirasawa A, Sugano K, Yoshida T, Ushiama M, Ueki A, Akahane T, Nanki Y, Sakai K, Makabe T, Yamagami W, Susumu N, Kameyama K, Kosaki K, Aoki D

    International cancer conference journal 10 ( 1 ) 6 - 10 2021.01

  • Survey of the clinical practice pattern of using sentinel lymph node biopsy in patients with gynecological cancers in Japan: the Japan Society of Gynecologic Oncology study

    Togami S., Kobayashi H., Niikura H., Shimada M., Susumu N., Tanaka T., Terai Y., Nagai T., Baba T., Yahata H., Yamagami W., Yamaguchi K., Yamashita T., Yaegashi N., Katabuchi H., Aoki D.

    International Journal of Clinical Oncology (International Journal of Clinical Oncology)   2021

    ISSN  13419625

     View Summary

    Background: Sentinel lymph node (SN) biopsy is essential for evaluating survival and minimal treatment-related morbidity associated with cervical, endometrial, and vulvar cancer in Japan. As such, our aim in this study was to evaluate the current practice pattern of using SN biopsy for cervical, endometrial, and vulvar cancer in Japan. Methods: We deployed a 47-question survey on the use of SN biopsy for gynecological cancers to 216 gynecological oncology training facilities. The survey included information on the use of SN biopsy for uterine (cervical and endometrial) and vulvar cancers; details on the type, timing, and concentration of tracers used; surgical approach used for SN biopsy; method of biopsy and pathological examination; and facilities’ experience with clinical research on SN biopsy. Results: The response rate was 84% (181/216), with 40 facilities (22%) having experience in SN biopsy for gynecological cancers, 34 (85%) for uterine cancers, and 15 (37%) for vulvar cancers. Radioisotope, indocyanine green (ICG), and blue dyes were available for the detection of uterine cancers in 21 (52%), 25 (62%), and 19 (48%) facilities and for vulvar cancers in 9 (22%), 3 (7%), and 11 (27%) facilities, respectively. Thirty-four facilities (85%) used intraoperative frozen section procedure for diagnosis when possible, with 24 (71%) of these facilities using 2-mm specimen cuts. Diagnosis included pathological examination (85%), immunostaining (57%), and one-step nucleic acid amplification (5%). Conclusion: Increasing research evidence, providing insurance coverage for radioisotope tracers, and increasing the availability of training are expected to increase the use of SN biopsy in Japan.

display all >>

Papers, etc., Registered in KOARA 【 Display / hide

display all >>

Reviews, Commentaries, etc. 【 Display / hide

  • The trend and outcome of postsurgical therapy for high-risk early-stage cervical cancer with lymph node metastasis in Japan: a report from the Japan Society of Gynecologic Oncology (JSGO) guidelines evaluation committee

    Masae Ikeda and Masako Shida and Shogo Shigeta and Satoru Nagase and Fumiaki Takahashi and Wataru Yamagami and Hidetaka Katabuchi and Nobuo Yaegashi and Daisuke Aoki and Mikio Mikami

    Journal of Gynecologic Oncology (Asian Society of Gynecologic Oncology$\mathsemicolon$ Korean Society of Gynecologic Oncology and Colposcopy)  32 ( 3 ) e44 2021

    ISSN  2005-0380

  • 【不妊・不育症女性の合併症・併存疾患をどう扱う?】婦人科悪性腫瘍

    山上 亘,上條 慎太郎,吉村 拓馬,平野 卓朗,坂井 健良,浜谷 敏生,青木 大輔

    産婦人科の実際 (金原出版)  69 ( 13 ) 1645 - 1651 2020.12

    Introduction and explanation (commerce magazine), Joint Work

  • 【内膜を極めるII-婦人科疾患の治療と内膜機能-】子宮内膜癌の機能温存療法

    進 伸幸, 山上 亘, 片岡 史夫, 岡田 智志, 田中 宏一, 青木 大輔

    産婦人科の実際 (金原出版(株))  69 ( 11 ) 1129 - 1135 2020.11

    ISSN  0558-4728

     View Summary

    <文献概要>若年子宮内膜癌患者は,晩婚化,少産化などのライフスタイルの変化により近年増加傾向にある。筋層浸潤のない類内膜癌G1(G1EC)または子宮内膜異型増殖症(AEH)が妊孕性温存治療の対象であり,子宮外病変(重複がん,転移,腹腔内播種)がないこと,漿液性癌などのホルモン不応性の成分の混在のないことの確認も重要である。わが国ではメドロキシプロゲステロン酢酸エステル(MPA)のみが保険診療として用いられている。MPA投与と反復内膜全面掻爬により比較的高い病変消失率が得られているが,不応例があること,高頻度に子宮内再発がみられること,卵巣癌などの重複がん症例が数%みられることなどにも注意を要する。再発症例に対する高用量MPA療法による再治療の前方視的臨床研究が,わが国で近々に開始となる予定である。

  • 臨床研修指導Q&A

    渡利 英道, 生水 真紀夫, 小松 宏彰, 井平 圭, 岩瀬 春子, 馬詰 武, 草開 妙, 甲賀 かをり, 近藤 英治, 関根 正幸, 中川 慧, 西ヶ谷 順子, 長谷川 潤一, 馬場 長, 林 昌子, 山上 亘, 伊東 優, 植田 彰彦, 上田 遥香, 大澤 有姫, 小野寺 洋平, 櫻木 俊秀, 品川 真奈花, 下地 裕子, 末光 徳匡, 杉田 洋佑, 玉田 祥子, 玉内 学志, 中野 和俊, 平山 貴士, 廣瀬 佑輔, 細川 義彦, 松尾 光徳, 的場 優介, 眞山 学徳, 日本産科婦人科学会産婦人科未来委員会

    日本産科婦人科学会雑誌 ((公社)日本産科婦人科学会)  72 ( 9 ) np1 - np38 2020.09

    Introduction and explanation (scientific journal), Joint Work,  ISSN  0300-9165

  • センチネルリンパ節生検の保険収載にむけた現状 センチネルリンパ節生検のトレーサーの適応拡大のための公知申請について

    山上 亘

    日本産科婦人科学会雑誌 ((公社)日本産科婦人科学会)  72 ( 臨増 ) S - 133 2020.03

    ISSN  0300-9165

display all >>

Presentations 【 Display / hide

  • 子宮体癌および子宮内膜異型増殖症に対する黄体ホルモン療法後の治療効果判定における子宮鏡検査の有用性に関する検討

    黒田由香, 山上亘, 吉村拓馬, 平野卓朗, 坂井 健良,真壁 健,千代田 達幸, 小林 佑介, 阪埜 浩司,青木 大輔

    第60回日本産科婦人科内視鏡学会学術講演会 (大阪市(WEB開催)) , 2020.12, Oral Presentation(general)

  • 卵巣境界悪性腫瘍に対する開腹手術と腹腔鏡下手術の比較検討

    同前 愛、千代田 達幸、高橋 美央、黒田 由香、吉村 拓馬, 平野 卓朗、山上 亘、青木 大輔

    第60回日本産科婦人科内視鏡学会学術講演会 (大阪市(WEB開催)) , 2020.12, Oral Presentation(general)

  • JGOG2051:子宮体癌/子宮内膜異型増殖症に対する妊孕性温存治療後の子宮内再発に対する反復高用量黄体ホルモン療法に関する第II相試験

    山上 亘

    婦人科悪性腫瘍研究機構(JGOG)総会 (東京(WEB開催)) , 2020.12, Other

  • MPA療法の治療効果判定における,子宮内膜細胞診の有用性について

    吉村拓馬,山上 亘,平野卓朗,坂井健良,真壁 健, 千代田達幸,阪埜浩司,進 伸幸,青木大輔

    第59回日本臨床細胞学会秋期大会 (横浜市) , 2020.11, Poster (general)

  • 当科における悪性卵巣腫瘍術後患者へのホルモン補充療法(HRT)の有用性に関する検討

    谷本 慧子, 横田 めぐみ, 千代田 達幸, 黒田 由香, 吉村 拓馬, 平野 卓朗, 山上 亘, 弟子丸 亮太, 岩田 卓, 阪埜 浩司, 青木 大輔

    第35回日本女性医学学会学術集会 (東京) , 2020.11, Oral Presentation(general)

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide

  • 若年子宮体癌に対する妊孕性温存ホルモン療法の予後予測因子の解明

    2020.04
    -
    2023.03

    日本学術振興会, 科学研究費助成事業, 山上 亘, Research grant, Principal Investigator

  • 子宮内膜異型増殖症・子宮体癌妊孕性温存療法に対するメトホルミンの適応拡大に向けた多施設共同研究

    2019.04
    -
    2023.03

    AMED, 臨床研究・治験推進研究事業, 三橋 暁, Research grant, Co-investigator

  • 子宮体癌/子宮内膜異型増殖症に対する妊孕性温存治療後の子宮内再発に対する反復高用量黄体ホルモン療法に関する第II相試験

    2019.04
    -
    2020.03

    土谷記念医学振興基金 研究助成, 進 伸幸, Research grant, Co-investigator

  • 婦人科悪性腫瘍の薬物応答に関与する新規バイオマーカーの特定

    2016.04
    -
    2019.03

    Grant-in-Aid for Scientific Research, Research grant, Principal Investigator

  • 卵巣癌の薬物応答に関与する新規バイオマーカーの特定

    2012.04
    -
    2015.03

    Grant-in-Aid for Scientific Research, Principal Investigator

Awards 【 Display / hide

  • 優秀査読者賞

    2020.11, 日本産科婦人科内視鏡学会

    Type of Award: Celebration by Official journal of a scientific society or Academic Journal

  • JGO Best Reviewer Award

    Wataru Yamagami, 2019.10, Asian Society of Gynecologic Oncology

    Type of Award: Celebration by Official journal of a scientific society or Academic Journal

  • JSOG Congress Encouragement Award

    2016.04, 第68回日本産科婦人科学会学術講演会, An analysis of short term recurrent cases following medroxyprogesterone acetate(MPA)therapy for endometrial cancer and atypical endometrial hyperplasia.

    Type of Award: International Academic Awards

  • 第52回日本癌治療学会学術集会優秀演題賞

    2014.08, 第52回日本癌治療学会学術集会, 子宮体癌におけるセンチネルリンパ節マッピングの検討

    Type of Award: Awards of National Conference, Council and Symposium

  • 第49回日本癌治療学会学術集会優秀演題賞

    2011.10, 第49回日本癌治療学会学術集会, 子宮肉腫に対するifosfamide、doxorubicin、cisplatin療法(IAP療法)の後方視的検討

    Type of Award: Awards of National Conference, Council and Symposium

display all >>

 

Courses Taught 【 Display / hide

  • LECTURE SERIES, GYNECOLOGY

    2021

  • LECTURE SERIES, GYNECOLOGY

    2020

  • 婦人科学 子宮体部腫瘍(治療)

    2019, Spring Semester, Major subject, Lecture, Within own faculty, 1h

  • 婦人科学 子宮体部腫瘍(治療)

    2018, Autumn Semester, Major subject, Lecture, Within own faculty, 1h

  • 婦人科学 子宮体部腫瘍(治療)

    2017, Autumn Semester, Major subject, Lecture, Within own faculty, 1h

display all >>

Courses Previously Taught 【 Display / hide

  • 婦人科学 子宮体癌治療

    Keio University, 2019, Spring Semester, Major subject, Lecture

  • 婦人科学 子宮体癌治療

    Keio University, 2018, Spring Semester, Major subject, Lecture

  • 婦人科学 子宮体癌治療

    Keio University, 2017, Spring Semester, Major subject, Lecture

  • 婦人科学 婦人科救急の考え方

    Keio University, 2016, Spring Semester, Major subject, Lecture

  • 婦人科学 婦人科救急の考え方

    Keio University, 2015, Spring Semester, Major subject, Lecture

display all >>

Educational Activities and Special Notes 【 Display / hide

  • 婦人科悪性腫瘍研究機構(JGOG)教育セミナー アドバイザー (第7回~第12回)

    2013.08
    -
    2018.08

    , Special Affairs

 

Memberships in Academic Societies 【 Display / hide

  • 日本産科婦人科学会

     
  • 日本婦人科腫瘍学会

     
  • 日本癌学会

     
  • 日本癌治療学会

     
  • 日本臨床細胞学会

     

display all >>

Committee Experiences 【 Display / hide

  • 2021.06
    -
    Present

    臨床研究審査委員会主務幹事・委員, 日本産科婦人科学会

  • 2021.06
    -
    Present

    副幹事長, 日本産科婦人科学会

  • 2021.06
    -
    Present

    婦人科悪性腫瘍登録システムの運用と精度管理に関する小委員会委員, 日本産科婦人科学会

  • 2021.06
    -
    Present

    コンプライアンス委員会副委員長, 日本産科婦人科学会

  • 2021.06
    -
    Present

    中央専門医制度委員会委員, 日本産科婦人科学会

display all >>